Taiyen Biotech Co (TPE:1737) Stock Based Compensation: NT$0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1737 Taiyen Biotech Co Ltd TPE:1737
82 GF Score
Price NT$32.15
GF Value NT$32.04
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Taiyen Biotech Co Stock Based Compensation?

Taiyen Biotech Co TPE:1737 +0.47% 82 Stock Based Compensation is NT$0 Mil as of Dec. 2025. GuruFocus rates TPE:1737 with a GF Score™ of 82/100 and a GF Value™ of NT$32.04 (Fairly Valued). The stock has 1 warning sign investors should review.

Taiyen Biotech Co's Stock Based Compensation for the three months ended in Dec. 2025 was NT$0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0 Mil.

Taiyen Biotech Co Stock Based Compensation Related Terms

Taiyen Biotech Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Taiyen Biotech Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiyen Biotech Co Stock Based Compensation Chart

Taiyen Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Taiyen Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:1737
82GF Score
Taiyen Biotech Co Ltd TPE:1737
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiyen Biotech Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0 Mil.

What does a Stock Based Compensation of NT$0 Mil mean?
Taiyen Biotech Co (TPE:1737) has a Stock Based Compensation of NT$0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Taiyen Biotech Co and its competitors.
Is Taiyen Biotech Co's Stock Based Compensation too high?
Taiyen Biotech Co's current Stock Based Compensation is NT$0 Mil. Overall, Taiyen Biotech Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's Stock Based Compensation compare to PG and CL?
Taiyen Biotech Co's Stock Based Compensation of NT$0 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Consumer Packaged Goods company?
A good Stock Based Compensation depends on the Consumer Packaged Goods industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Taiyen Biotech Co and its competitors. Taiyen Biotech Co's current Stock Based Compensation is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$32.04, compared to a current price of NT$32.15 — trading 0.3% above its estimated fair value. The current Stock Based Compensation is NT$0 Mil. Taiyen Biotech Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current Stock Based Compensation is NT$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?

Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be overvalued. The current stock price of NT$32.15 is trading 0.3% above its estimated GF Value™ of NT$32.04. GuruFocus considers Taiyen Biotech Co to be Fairly Valued.

Key valuation signals for TPE:1737:

  • Stock Based Compensation: NT$0 Mil
  • GF Value™: NT$32.04 vs. price of NT$32.15 (0.3% above fair value)
  • GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiyen Biotech Co Business Description

Address No. 297, Section 1, Chien-Kang Road, South District, Tainan, TWN
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
82GF Score

Get the complete analysis for TPE:1737

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.15
Price
NT$32.04
GF Value